Haug H J
Pharmacopsychiatry. 1987 Feb;20(1 Spec No):35-7. doi: 10.1055/s-2007-1017127.
The few patients examined in the pilot study so far lead us to believe that the new neuroleptic drug zotepine is a substance with good antipsychotic effectiveness. Among the side-effects, a marked sedative component is apparent which is perceived as being unpleasant by all patients due to its expression in the form of drowsiness and lack of vitality during the day. Here, problems with patient compliance may possibly arise. Extrapyramidal motor side-effects could not be observed except in one case in which therapy was consequently terminated. The changes observed in the EEG were interpreted as an increase in cerebral excitability, an effect known to be possible in connection with the administration of neuroleptic drugs. Altogether, on the basis of our first clinical experience with the new neuroleptic zotepine, we feel that this drug doses not yield a marked improvement in regard to the ratio of effect to side-effect when compared with the other neuroleptic drugs available at the present time. Our findings, however, tend to support suggestions in the literature that zotepine may have a better effect than other drugs on patients' negative symptoms.
到目前为止,在初步研究中接受检查的少数患者让我们相信,新型抗精神病药物佐替平是一种具有良好抗精神病效果的物质。在副作用方面,明显存在显著的镇静成分,所有患者都认为这令人不适,因为它表现为嗜睡以及白天缺乏活力。在此,可能会出现患者依从性的问题。除了有一例因此终止治疗的情况外,未观察到锥体外系运动副作用。脑电图观察到的变化被解释为大脑兴奋性增加,已知使用抗精神病药物可能会出现这种效应。总体而言,基于我们使用新型抗精神病药物佐替平的首次临床经验,我们认为与目前可用的其他抗精神病药物相比,这种药物在疗效与副作用的比率方面并没有显著改善。然而,我们的研究结果倾向于支持文献中的观点,即佐替平对患者的阴性症状可能比其他药物有更好的效果。